Hubei Guangji Pharmaceutical Co., Ltd.

Simbol: 000952.SZ

SHZ

6.12

CNY

Tržna cena danes

  • -14.2334

    Razmerje P/E

  • -0.0163

    Razmerje PEG

  • 2.10B

    Kapaciteta MRK

  • 0.00%

    Donos DIV

Hubei Guangji Pharmaceutical Co., Ltd. (000952-SZ) Finančni izkazi

Na grafu so prikazane privzete številke v dinamiki za Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ). Prihodki podjetja prikazujejo povprečje 470.101 M, ki je 0.079 % gowth. Povprečni bruto dobiček za celotno obdobje je 170.696 M, ki je 0.215 %. Povprečno razmerje bruto dobička je 0.353 %. Rast čistega dobička za lanskoletno poslovanje podjetja je -3.786 %, kar je enako -2.383 % % v povprečju v celotni zgodovini podjetja.,

Bilanca stanja

Če pogledamo fiskalno pot podjetja Hubei Guangji Pharmaceutical Co., Ltd., opazimo povprečno rast sredstev. Zanimivo je, da ta stopnja znaša , kar odraža tako visoke kot tudi padce podjetja. Pri primerjavi četrtletja s četrtletjem se ta številka prilagodi na 0. Pogled nazaj v preteklo leto razkrije skupno spremembo sredstev v višini 0.227. Na področju kratkoročnih sredstev 000952.SZ znaša 1084.666 v valuti poročanja. Velik del teh sredstev, natančneje 415.244, je v denarju in kratkoročnih naložbah. V tem segmentu se je ob primerjavi s podatki za preteklo leto spremenil za -0.037%. Dolgoročne naložbe podjetja, ki sicer niso v središču njegovega zanimanja, znašajo 45.355, če obstajajo, v valuti poročanja. To pomeni razliko v višini 2.773% glede na zadnje obdobje poročanja, kar odraža strateške premike družbe. Dolgoročni profil podjetja kaže skupni dolgoročni dolg v višini 419.537 v valuti poročanja. Ta številka pomeni medletno spremembo v višini 0.546%. Vrednost za delničarje, kot jo prikazuje celotni lastniški kapital, je ovrednotena z vrednostjo 1363.446 v valuti poročanja. Letna sprememba tega vidika je -0.093%. Podrobnejši pregled finančnih podatkov podjetja razkrije dodatne podrobnosti. Neto terjatve so ovrednotene na 350.696, zaloge na 298.99, dobro ime pa na 0, če obstaja. Celotna neopredmetena sredstva, če so prisotna, so ovrednotena z vrednostjo 216.91. Obveznosti in kratkoročni dolgovi so 29.87 oziroma {{short_term_deby}}. Celotni dolg je 935.86, neto dolg pa je 520.62. Druge kratkoročne obveznosti znašajo 90.93 in se dodajo k skupnim obveznostim 1637.07. Nazadnje se navedena zaloga vrednoti po vrednosti {{preffered_stock}}, če obstaja.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

balance-sheet.row.cash-and-short-term-investments

2401.91415.2431.4293.3
350.3
183.7
173.6
140.8
116.7
161.9
194.8
111
125
152.3
211.8
188.8
220.1
172.2
72.6
32.1
45.7
69.1
135.8
95.5
117.1
113.2
6.9
2.9
2.8

balance-sheet.row.short-term-investments

-21.47-10.200
-0.1
-0.4
-0.5
-0.5
0
0
0
0
0
0
0
0
0
0.3
10.5
10
10
11
0
0
25
30
0
0
0

balance-sheet.row.net-receivables

1407.13350.7339.9238.5
169.6
172.3
177.4
161.7
167.1
139.4
76.7
231.9
134
149
180.3
245.2
257.7
202.5
209.8
381.2
389.2
390.7
201.8
205.1
41.2
24.9
17.5
4.7
8.1

balance-sheet.row.inventory

1249.74299221.5164.8
163.6
137.9
98.5
98.4
109.2
98.9
151.5
170.8
181.9
203.7
97.6
52.4
91.4
60.7
50.9
60
62.4
61.8
59.9
59.6
48.8
55.6
84.5
78
41.6

balance-sheet.row.other-current-assets

68.4219.712.712.3
18.6
20.4
19.1
19.7
23.2
32.6
55
-63
-25.1
-24.1
-32.9
-46.5
-43.3
0.7
-44.3
-106.8
-108
-125.5
2
9.4
127.8
138.7
126.8
100.6
56.9

balance-sheet.row.total-current-assets

5127.211084.71005.5709
702.1
514.3
468.6
420.5
416.3
432.8
477.9
450.8
415.8
481
456.8
439.9
526
436
288.9
366.5
389.3
396
399.4
369.6
334.9
332.5
235.6
186.3
109.3

balance-sheet.row.property-plant-equipment-net

5756.251637.11199.21069.2
1041.9
963.4
959.5
969.3
974.5
942.5
854.6
858.4
863.8
865.8
780.5
684.9
502.9
376.5
336.8
353.2
352.5
325.4
277.5
256.6
218.8
223.3
107
108.3
96.7

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

728.73216.9150.6154.7
161.6
168.5
165.5
169.3
183
191.8
193.5
196.9
190.9
75
62.6
65
83.9
53.7
38.6
41.9
45.5
49.8
53.2
47.3
37.5
36.6
34.3
36.5
37

balance-sheet.row.goodwill-and-intangible-assets

728.73216.9150.6154.7
161.6
168.5
165.5
169.3
183
191.8
193.5
196.9
190.9
75
62.6
65
83.9
53.7
38.6
41.9
45.5
49.8
53.2
47.3
37.5
36.6
34.3
36.5
37

balance-sheet.row.long-term-investments

167.1945.444.139.8
22.8
27.8
32.1
34.5
0
0
0
0
0
77.9
0
0
0
107.3
108.2
108.1
109.1
78.3
0
0
58.8
23.6
0
0
0

balance-sheet.row.tax-assets

90.7315.926.824.8
21.8
17.6
18.6
21.5
0
0
0
6.5
5.1
6.9
6.2
7.6
12.5
25
11.9
12.2
12.9
14.7
0
0
25.5
32
0
0
0

balance-sheet.row.other-non-current-assets

59629.642.851.4
29.4
74.9
49
26.7
60.1
53.6
56.4
39.2
80.4
0
78.4
106.4
81.8
0.3
0.6
0.6
2.6
2.6
89.7
88.3
0.7
0.8
1.8
2
1.9

balance-sheet.row.total-non-current-assets

7338.91944.91463.61339.9
1277.4
1252.2
1224.7
1221.4
1217.6
1187.9
1104.5
1101
1140.2
1025.7
927.6
864
681.1
562.8
496.1
516
522.7
470.9
420.5
392.2
341.3
316.3
143.1
146.8
135.6

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

12466.113029.52469.12048.9
1979.4
1766.5
1693.3
1641.9
1633.9
1620.7
1582.5
1551.8
1556
1506.7
1384.4
1303.8
1207.1
998.8
785
882.4
912
866.9
819.9
761.8
676.2
648.8
378.8
333
244.9

balance-sheet.row.account-payables

542.15143178.6121.6
139.1
104.4
103.2
118.5
162.8
254.2
290.6
332.4
307.4
161.5
96.1
98.5
90.1
54.6
51.8
40
66
62.3
59.1
50.6
42.2
18.9
22.3
39.3
4.4

balance-sheet.row.short-term-debt

2189.84516.3357.2336.7
219.4
521.7
524.4
531.4
506.9
207.7
189
202.2
251.5
264
207.1
135
81
68
135
192
208.2
178.2
175.2
149.8
45.4
79.4
125.4
62
46.5

balance-sheet.row.tax-payables

43.6412.117.613.6
18.6
7.2
14.2
29.8
17.6
9
13.6
-28.6
-34
-30.9
-16.7
-5.7
96.4
112
-3.3
-5.5
-7.8
-4.3
-7
-0.9
7.6
9.5
3.4
0.3
-0.3

balance-sheet.row.long-term-debt-total

1740.97419.5248.136.1
84.4
74.8
27.5
80.5
132.6
308
317
79.5
124.6
103.5
121.8
142.7
0
10
77.5
72
83.2
73
50
40
69
48
7.1
38
36.5

Deferred Revenue Non Current

63.7915.718.121
23.3
25.8
27.5
31.3
34.4
43.6
49.7
47.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

751.08---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

305.0590.9112.70.9
2.6
5.7
86.2
20.9
28.8
15.8
31.1
15.3
14.6
8.8
11.4
11.6
7.8
13.7
15.3
14.5
11.6
14.5
15.4
9.6
5.6
2.8
0.1
6.3
0.1

balance-sheet.row.total-non-current-liabilities

3276.47771.2323.257.8
153.3
100.6
84.3
113.9
179.7
545.8
383.1
127.5
158.8
122.6
140.5
158.2
16.8
10
77.5
79.1
84.1
73.5
50.1
40.1
69.1
51.1
10.8
41.1
39.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

9.862.23.21.6
0
27
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

6780.931637.1977.2598.1
613.7
802.2
812.3
876.6
974.7
1106.9
1077
816.8
795.9
643.1
545.1
486.9
395.8
325.8
307.3
350.7
388.8
352.4
313
275
194.7
199.5
186.8
166.8
110.7

balance-sheet.row.preferred-stock

0.01000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1415.67353.9354344
347
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
251.7
171.2
171.2
171.2
171.2
171.2
171.2
171.2
121.2
121.2
86.6

balance-sheet.row.retained-earnings

2151.24502.7644.6626.9
554.4
584.9
505.8
368.4
265.7
123.9
102.9
321.7
319.3
414.8
412.3
401.7
363.1
308.4
139.3
125.3
118
111
104.4
87.6
84.3
56.8
44.7
22.8
30.2

balance-sheet.row.accumulated-other-comprehensive-income-loss

754.230158.5172.2
155.4
127.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

1286.99506.9345.6319.3
316.4
-3.8
115.7
139.2
136.6
136.6
143.5
143.5
148
149.5
142.4
139.1
133.4
107.1
86.2
234.9
233.6
232.3
231.2
228.1
226
221.3
26
22.2
17.4

balance-sheet.row.total-stockholders-equity

5608.141363.41502.61462.5
1373.1
960.4
873.3
759.2
654
512.2
498.2
716.9
718.9
816
806.5
792.5
748.3
667.2
477.3
531.3
522.8
514.6
506.9
486.9
481.5
449.3
192
166.2
134.2

balance-sheet.row.total-liabilities-and-stockholders-equity

12466.113029.52469.12048.9
1979.4
1766.5
1693.3
1641.9
1633.9
1620.7
1582.5
1551.8
1556
1506.7
1384.4
1303.8
1207.1
998.8
785
882.4
912
866.9
819.9
761.8
676.2
648.8
378.8
333
244.9

balance-sheet.row.minority-interest

77.0529-10.8-11.7
-7.4
3.9
7.7
6
5.2
1.7
7.3
18.1
41.1
47.6
32.9
24.4
63
5.8
0.4
0.4
0.4
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

5685.191392.41491.81450.8
1365.7
964.3
881
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

12466.11---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

145.7235.244.139.8
22.6
27.4
31.6
34
35.5
38.9
39.4
39
80.4
78
78.4
106.4
81.8
107.6
118.7
118.1
119.1
89.3
87
87.4
83.8
53.6
0
0
0

balance-sheet.row.total-debt

3930.81935.9605.4372.8
303.8
596.5
551.9
531.4
506.9
515.7
506
281.7
376.1
367.5
329
277.7
81
78
212.5
264
291.4
251.2
225.2
189.8
114.4
127.4
132.5
100
82.9

balance-sheet.row.net-debt

1528.9520.617479.5
-46.5
412.8
378.4
390.5
390.2
353.8
311.2
170.7
251.1
215.2
117.2
88.9
-139.1
-94.2
150.4
241.9
255.7
193.1
89.4
94.3
22.3
44.2
125.7
97
80.1

Izkaz denarnih tokov

V zadnjem obdobju se je v finančnem okolju Hubei Guangji Pharmaceutical Co., Ltd. opazno spremenil prosti denarni tok, ki se je spremenil v -3.508. Podjetje je nedavno povečalo svoj osnovni kapital z izdajo 0, kar kaže na razliko -0.032 v primerjavi s prejšnjim letom. Zanimivo je, da je del delnic podjetja, natančneje 0, odkupilo podjetje samo. To dejanje je povzročilo spremembo v 0.000 v primerjavi s prejšnjim letom. Medtem pa obveznosti podjetja trenutno znašajo 29.87 v valuti poročanja. Družba je pri naložbenju porabila neto denarna sredstva v višini -121737831.980 v valuti poročanja. To je premik za 0.067 v primerjavi s prejšnjim letom. V istem obdobju je družba zabeležila 98.31, -3.49 in -415.44, ki so pomembne za razumevanje naložbenih in odplačilnih strategij podjetja. Družba je pri financiranju porabila 0.000, pri čemer je razlika v primerjavi z letom prej znašala 0.000. Poleg tega je podjetje namenilo -40.24 za izplačilo dividend svojim delničarjem. Hkrati je izvajalo tudi druge finančne manevre, imenovane 756.62, ki so prav tako pomembno vplivali na denarni tok v tem obdobju. Te sestavine skupaj tvorijo celovito sliko finančnega stanja podjetja in strateškega pristopa k upravljanju denarnih tokov.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

-146.7247.7105.870.3
83.2
173.4
106.1
145.3
18.4
-229.6
-5
-103.5
0.8
9.4
37.2
97.3
195.6
15.7
8.6
8.1
7.7
19.9
24.6
30.6
31.4
25.7

cash-flows.row.depreciation-and-amortization

94.6398.391.390.4
81.3
82.8
82.5
73.1
54.4
68.2
66.9
62.2
58.8
52.8
37.9
34.2
30.4
30.8
28.1
23.9
22.5
19.3
20.3
12.2
14
11.9

cash-flows.row.deferred-income-tax

-0.1-2.3-2.7-4.1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

7.289.52.74.1
-1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

-152.33-138.8-121.4-50.9
-61.9
-63.2
-78.5
-99.1
-171.8
-24.1
32.4
115.4
-1.6
1.9
-85.6
67.1
50.1
44.3
-4.8
-50.4
-64.8
24.4
-87.4
6.3
9.8
-53.6

cash-flows.row.account-receivables

-53.06-102.1-66.9475.9
2.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-100.18-64.3-4.3-26.8
-43
3.1
10.9
-11.5
48.2
-5.5
10.5
23.4
-109.4
-46.7
38
-30.7
0.4
9.2
0.9
-0.6
-1.9
-0.5
10.8
6.4
28.2
-6.5

cash-flows.row.account-payables

029.9-47.4-495.7
-22.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0.91-2.3-2.7-4.1
1
-66.4
-89.3
-87.6
-220
-18.6
21.9
92
107.7
48.6
-123.6
97.8
49.7
35.1
-5.7
-49.8
-62.9
24.9
-98.2
-0.1
-18.4
-47.1

cash-flows.row.other-non-cash-items

70.3430.70.29.5
41.7
38.4
68.7
47.8
65.6
110.8
0.9
33.9
23.9
13.1
-13.8
22
55.8
35.2
22.3
15
19.2
12.6
20.1
-0.5
13.3
0.6

cash-flows.row.net-cash-provided-by-operating-activities

-134.19000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-559.78-203.7-96.6-97.9
-119.8
-76.5
-80.9
-112.9
-109.9
-94.6
-50
-117.5
-201
-115.6
-149.9
-219.8
-48.9
-18.7
-25.8
-47.6
-65.7
-50.5
-46.8
-25.1
-135.6
-3

cash-flows.row.acquisitions-net

523.50.741.4
0.1
0
0
0
110
1.2
59.8
117.7
12.4
13
13.3
0.1
-1.2
0
26
47.6
66.1
0
0
25.6
0
0

cash-flows.row.purchases-of-investments

0-10-80-830
-0.1
0
0
0
-10
-34
-2
-8
-7
-8
-67.6
-15
-29.6
-2.3
-0.9
-13
-20.4
-2
-9
-21.6
-83.6
0

cash-flows.row.sales-maturities-of-investments

-749261.8773.5
0.1
0.2
0.2
2.5
0.3
38.4
37.5
7.1
8
12.3
10.4
10
1.5
0
1.9
13
10
0
26
8
0
0

cash-flows.row.other-investing-activites

0.35-3.500.2
0.1
0.1
1
1.4
-109.9
10
-50
-117.5
16.3
2.5
0.5
56
0.4
0.1
-25.8
-47.6
-65.7
0.6
10
-25.1
0.5
0

cash-flows.row.net-cash-used-for-investing-activites

-559.42-121.7-114.1-112.8
-119.5
-76.2
-79.7
-109.1
-119.6
-79
-4.8
-118.1
-171.3
-95.7
-193.3
-168.7
-77.8
-21
-24.7
-47.5
-75.8
-51.9
-19.8
-38.2
-218.6
-3

cash-flows.row.debt-repayment

-344-415.4-399.5-680.1
-563.9
-495.7
-476
-148
-272.7
-357.1
-355.8
-356.2
-326.5
-177.7
-150
-102
-226.5
-205.3
-168.2
-154.7
-190.2
-37.9
-47.4
-51.1
-53.1
-21.7

cash-flows.row.common-stock-issued

000-5.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0005.9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

-36.9-40.2-35.7-49.5
-29.3
-50.9
-31.8
-35.5
-36.1
-21.2
-26.4
-25.8
-21.1
-12.8
-6.2
-26.7
-10.4
-13.5
-15.7
-11.8
-12.5
-19.4
-9.6
-13.1
-12.5
-10.9

cash-flows.row.other-financing-activites

931.87756.6388.4832.7
576.5
424.2
440
87.7
423.7
619.6
261.4
364.8
377.5
232
342.6
124.7
92
153.8
140.8
194.9
216.2
73.3
102.6
62.7
292.1
54.8

cash-flows.row.net-cash-used-provided-by-financing-activities

707.19300.9-46.8103.1
-16.8
-122.4
-67.8
-95.9
114.9
241.2
-120.8
-17.2
29.9
41.5
186.4
-4.1
-144.9
-65
-43.1
28.4
13.5
16
45.6
-1.5
226.4
22.2

cash-flows.row.effect-of-forex-changes-on-cash

0.781.4-1.5-3.8
2.2
-0.1
2.8
0.1
0.2
0
0
0
0
0
0
0
0
0
0.1
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

14.36225.7-86.5105.9
10.1
32.7
34.2
-37.7
-37.8
87.5
-30.4
-27.3
-59.4
22.9
-31.3
47.9
109.3
40
-13.5
-22.4
-77.7
40.3
3.4
8.9
76.4
4

cash-flows.row.cash-at-end-of-period

2397.91428.8203.1289.5
183.7
173.6
140.8
106.7
144.4
182.2
94.6
125
152.3
211.8
188.8
220.1
172.2
62.1
22.1
35.7
58.1
135.8
95.5
92.1
83.2
6.9

cash-flows.row.cash-at-beginning-of-period

2383.56203.1289.5183.7
173.6
140.8
106.7
144.4
182.2
94.6
125
152.3
211.8
188.8
220.1
172.2
62.9
22.1
35.7
58.1
135.8
95.5
92.1
83.2
6.9
2.9

cash-flows.row.operating-cash-flow

-134.1945.175.9119.4
144.2
231.4
178.8
167.1
-33.3
-74.7
95.2
108
81.9
77.2
-24.3
220.7
332
126
54.1
-3.3
-15.4
76.2
-22.4
48.6
68.6
-15.3

cash-flows.row.capital-expenditure

-559.78-203.7-96.6-97.9
-119.8
-76.5
-80.9
-112.9
-109.9
-94.6
-50
-117.5
-201
-115.6
-149.9
-219.8
-48.9
-18.7
-25.8
-47.6
-65.7
-50.5
-46.8
-25.1
-135.6
-3

cash-flows.row.free-cash-flow

-693.96-158.6-20.721.5
24.4
154.9
97.9
54.1
-143.3
-169.3
45.1
-9.4
-119.1
-38.4
-174.3
0.9
283
107.2
28.3
-50.9
-81.1
25.7
-69.2
23.5
-67
-18.2

Vrstica izkaza poslovnega izida

Prihodki Hubei Guangji Pharmaceutical Co., Ltd. so se v primerjavi s prejšnjim obdobjem spremenili za -0.075%. Bruto dobiček podjetja 000952.SZ znaša 202.2. Odhodki iz poslovanja podjetja so 275.42 in so se v primerjavi s prejšnjim letom spremenili za 31.791%. Odhodki za amortizacijo znašajo 98.31, kar je 0.220% sprememba glede na zadnje obračunsko obdobje. Stroški poslovanja so sporočeni v višini 275.42, ki kaže 31.791% spremembo glede na preteklo leto. Stroški prodaje in trženja znašajo 0, kar pomeni 0.000% spremembo v primerjavi s preteklim letom. EBITDA na podlagi zadnjih podatkov znaša 0 in predstavlja -2.445% rast v primerjavi s preteklim letom. Prihodki iz poslovanja so -141.05, ki kažejo -2.445% spremembo v primerjavi s preteklim letom. Sprememba čistih prihodkov je -3.786%. Čisti prihodki v zadnjem letu so znašali -140.25.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996

income-statement-row.row.total-revenue

802.69737.8797.6837.1
688.2
731.3
843.8
801.6
714.7
560.4
485.9
487.1
394.2
453.3
483.3
448.2
571.8
794.9
388.7
345.8
276.6
204.1
202.2
186.1
134.1
176.6
161.3
141.2
114.9

income-statement-row.row.cost-of-revenue

592.07535.6502.5535.9
408.5
391.5
364.4
393.6
341.7
379.3
440.5
427.2
380.6
359.4
388.6
353.9
341.2
337.9
271.5
260.9
209.1
130.8
127.3
105.5
68.8
98.2
89.3
71.1
68.6

income-statement-row.row.gross-profit

210.62202.2295.1301.2
279.6
339.8
479.5
407.9
373
181.1
45.3
59.9
13.6
93.9
94.7
94.3
230.6
457
117.2
85
67.5
73.3
74.9
80.6
65.4
78.4
72
70.2
46.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

74.42---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

93.38---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

39.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

1.890.46257.5
53.8
42.3
-4.1
-13.7
-1.3
17
5.6
51.6
17.3
7.1
11.5
2.8
3.2
0.8
-8.4
-2
-0.5
0.2
0
-0.2
-0.1
9.8
-0.3
0.1
0.1

income-statement-row.row.operating-expenses

290.39275.4209185.4
172.6
203.3
228
198
171
116.7
155.9
107.8
94.6
75.5
76
68.9
99.8
125.1
69.7
49
40.9
41
36.6
31.9
25.6
32.1
30.3
23.9
18.9

income-statement-row.row.cost-and-expenses

882.46811711.5721.2
581.2
594.8
592.3
591.6
512.7
496
596.4
535
475.2
434.9
464.6
422.7
441
463
341.2
309.9
250
171.8
163.9
137.4
94.4
130.3
119.6
95
87.5

income-statement-row.row.interest-income

3.43.523.2
1.4
1.1
0.6
0.7
1.3
2.6
2.6
2.2
1.2
5.5
1.2
0
2.8
1.1
0.3
0.3
0.3
0.4
1.2
0.8
0.8
0
0
0
0

income-statement-row.row.interest-expense

52.9549.221.116.7
32.6
35.1
30.7
33.7
36.3
35.8
25
28.8
24.9
21.1
12.8
4.6
5
10.9
13.5
15.9
11.8
11.7
11.5
9.2
5.8
12.1
10.9
11.3
8.3

income-statement-row.row.selling-and-marketing-expenses

39.31---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

1.890.4-37.56.1
-8.7
-37.1
-44.5
-88.4
-46.4
-46
-112.5
41.5
-21
-14.2
-3.1
18.1
-13.3
-49.3
-21.9
-19.7
-13.9
-14.2
-10.9
-16.6
-3.1
-2.3
-11.3
-11.2
-8.8

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

1.890.46257.5
53.8
42.3
-4.1
-13.7
-1.3
17
5.6
51.6
17.3
7.1
11.5
2.8
3.2
0.8
-8.4
-2
-0.5
0.2
0
-0.2
-0.1
9.8
-0.3
0.1
0.1

income-statement-row.row.total-operating-expenses

1.890.4-37.56.1
-8.7
-37.1
-44.5
-88.4
-46.4
-46
-112.5
41.5
-21
-14.2
-3.1
18.1
-13.3
-49.3
-21.9
-19.7
-13.9
-14.2
-10.9
-16.6
-3.1
-2.3
-11.3
-11.2
-8.8

income-statement-row.row.interest-expense

52.9549.221.116.7
32.6
35.1
30.7
33.7
36.3
35.8
25
28.8
24.9
21.1
12.8
4.6
5
10.9
13.5
15.9
11.8
11.7
11.5
9.2
5.8
12.1
10.9
11.3
8.3

income-statement-row.row.depreciation-and-amortization

72.0912098.3114.7
119.6
81.3
82.8
82.5
73.1
54.4
68.2
66.9
62.2
58.8
52.8
37.9
34.2
30.4
30.8
28.1
23.9
22.5
19.3
20.3
12.2
14
11.9
10.6
7.9

income-statement-row.row.ebitda-caps

-79.85---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

-151.94-141.197.6118.2
96.8
137
211.1
135.3
159.2
21.9
-226.5
-58.1
-118.7
-2.8
5.3
40.8
114.3
281.7
33.8
18.2
13.2
17.9
27.3
32.3
37
34.2
30.8
35.6
19.5

income-statement-row.row.income-before-tax

-150.05-140.760.1124.3
88.1
99.9
207.1
121.6
155.6
18.4
-223.1
-6.4
-102
4.2
15.6
43.6
117.5
282.6
25.5
16.2
12.7
18.1
27.3
32.1
36.8
44
30.4
35.4
19.1

income-statement-row.row.income-tax-expense

11.6311.712.418.5
17.8
16.7
33.7
15.5
10.3
0
6.5
-1.5
1.6
3.4
6.2
6.4
29.9
99.8
9.8
7.7
4.5
10.4
7.4
7.5
6.1
12.6
4.7
3.3
1.7

income-statement-row.row.net-income

-146.72-140.250.3110.1
74.6
86.9
171.7
105.2
141.8
20.9
-218.7
2.4
-95.6
4.8
14
43
89.1
183.8
15.7
8.6
8.2
7.7
19.9
24.6
30.6
31.4
25.7
32
17.4

Pogosto zastavljeno vprašanje

Kaj je Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) skupna sredstva?

Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) skupna sredstva so 3029517090.000.

Kakšen je letni prihodek podjetja?

Letni prihodki so 395486306.000.

Kolikšna je stopnja dobička podjetja?

Dobiček podjetja je 0.262.

Kakšen je prosti denarni tok podjetja?

Prosti denarni tok je -1.961.

Kolikšna je neto stopnja dobička podjetja?

Čista stopnja dobička je -0.183.

Kolikšni so skupni prihodki podjetja?

Celotni prihodki so -0.189.

Kaj je Hubei Guangji Pharmaceutical Co., Ltd. (000952.SZ) čisti dobiček (čisti dobiček)?

Čisti dobiček (čisti prihodek) je -140248068.540.

Kolikšen je skupni dolg podjetja?

Skupni dolg je 935859479.000.

Kolikšni so stroški poslovanja?

Stroški poslovanja so 275418481.000.

Kolikšno je število denarnih sredstev podjetja?

Denarna sredstva podjetja so 403741511.000.